Financials
Financial year 2025
PharmaNutrics from Deerlijk, company number BE0848304689, closed financial year 2025 with a result of € 77,572 after tax. For that financial year PharmaNutrics recorded a gross margin of € 207,473 and equity of € 77,925. Compared with financial year 2024, the result moved from € -38,328 to € 77,572. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.
€ 77,925
▲ € 77,572 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 77,572
▲ still € 38,328 loss in 2024
Profit after tax over the fiscal year.
€ 29,538
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 59,325.
People and assets in 2025
0.9
Average over the fiscal year, from the social balance sheet.
€ 95,601
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,257
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 14,677
▼ 40% vs 2024
€ 8,686 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 61,591
▼ 39% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,966
▲ 33% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 86,901 | € 94,421 | € 98,961 | € 207,473 | ▲ 110% |
| Profit after taxes | € 12,174 | € -48,186 | € -38,328 | € 77,572 | ▲ € 115,901 |
| Equity | € 86,867 | € 38,681 | € 353 | € 77,925 | ▲ € 77,572 |
| Total debts | € 280,649 | € 311,959 | € 350,437 | € 311,190 | ▼ 11% |
| Cash | € 12,917 | € 30,854 | - | € 29,538 | |
| Retained profit | € 68,267 | € 20,081 | € -18,247 | € 59,325 | ▲ € 77,572 |
| Bank debt | € 0 | € 31,018 | € 24,398 | € 14,677 | ▼ 40% |
| Balance sheet total | € 367,517 | € 350,641 | € 350,790 | € 389,115 | ▲ 11% |
| Employees (FTE) | 0.5 | 1.3 | 0.9 | 0.9 |
Key figures of PharmaNutrics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PharmaNutrics?
What happened at PharmaNutrics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 77,572. Source: NBB ↗
- Osteolab BV became a director. NBB
- Apothekers Beke-Debusschere became a director. NBB
- New establishment in Deerlijk. KBO
- Start of the company according to the CBE. KBO
In short
From € 12,174 profit in 2022 to € 77,572 profit in 2025.
Paid € 9,656 in corporate taxes since 2022.
Best year ever: 2025, with € 77,572 profit.
On average € 72,600 of value added per employee in 2023.
A new publication or filing at PharmaNutrics? We notify you, reason included.
Follow PharmaNutricsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of R.D.S., PEPHIL comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PharmaNutricsBehind PharmaNutrics are Osteolab BV and Apothekers Beke-Debusschere. The shares are held by R.D.S. (10.2%) and PEPHIL (10.2%).
Directors
According to the 2025 annual accounts
Director · represented by Egwin Ponette
since 2020
Director · represented by Nikolaas Debusschere
since 2014
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Hoogstraat 43
8540 Deerlijk
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0848.304.689
- VAT number
- BE 0848.304.689
- Registered office
- Hoogstraat 43, 8540 Deerlijk
- Names & denominations
- PharmaNutrics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 2012
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in andere voedingsmiddelen, neg
Overige detailhandel in voedingsmiddelen, neg
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.